

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Andrew Baxter et al.  
 Serial No. : 10/579,545  
 Filed : May 16, 2006  
 Title : NOVEL COMPOUNDS

Art Unit : Unknown  
 Examiner : Unknown  
 Conf. No. : 3967

MAIL STOP AMENDMENT  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 2004/005295, WO 2005/037814, WO/2005/040167, WO 2005/054249 and WO/2005/061499 are also enclosed.

Applicants provide a listing below of commonly owned co-pending U.S. patent applications that are included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent applications were filed as U.S. national phase patent applications under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for each of commonly owned co-pending U.S. patent applications.

The PTO-1449 lists the commonly owned co-pending U.S. patent applications by their corresponding published PCT publication numbers. The published U.S. patent applications are listed on the PTO-1449 under both the U.S. publication numbers and the PCT publication numbers.

U.S. Patent Application Serial No./  
 Published U.S. Patent Application

US-2005-0245741-A1  
 US 2007-0021498-A1  
 10/575,525  
 10/581,171  
 10/583,468

Corresponding Published PCT  
 Patent Application

WO 2004/005295 (previously cited in 5/16/06 IDS)  
 WO 2005/037814  
 WO 2005/040167  
 WO 2005/054249  
 WO 2005/061499

Applicant : Andrew Baxter et al.  
Serial No. : 10/579,545  
Filed : May 16, 2006  
Page : 2 of 2

Attorney's Docket No.: 06275-510US1 / 101279-1P US

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-510US1.

Respectfully submitted,

Date: \_\_\_\_\_

4 March 8, 2007

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21579871.doc

Catherine M. McCarty Reg. No. 54,301  
for Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-510US1	Application No. 10/579,545
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Andrew Baxter et al.	
		Filing Date May 16, 2006	Group Art Unit Unknown

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,010,201	03/01/1977	Lednicer			
	AB	4,263,317	04/21/1981	Martin et al.			
	AC	US-2005-0245741-A1	11/03/2005	Hossain et al.			
	AD	US 2007-0021498 A1	01/25/2007	Hossain			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE	EP 0004952	10/31/1979	Europe			Abstract	
	AF	EP 0417631	03/20/1991	Europe			Abstract	
	AG	EP 0722941	07/24/1996	Europe				
	AH	EP 1061076	12/20/2000	Europe				
	AI	WO 92/10096	06/25/1992	WIPO				
	AJ	WO 96/36625	11/21/1996	WIPO				
	AK	WO 01/30780	05/03/2001	WIPO				
	AL	WO 02/102387	12/27/2002	WIPO				
	AM	WO 03/037271	05/08/2003	WIPO				
	AN	WO 2005/037814	04/28/2005	WIPO				
	AO	WO 2005/040167	05/06/2005	WIPO				
	AP	WO 2005/054249	06/16/2005	WIPO				
	AQ	WO 2005/061499	07/07/2005	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AR	Mehrotra et al., "Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR of Potent and Specific 2,8-Diazaspiro[4.5]decanes", Bioorganic & Medicinal Chemistry Letters 12:1103-1107 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	